[Translated article] RF – Should Striae be Considered a Predisposing Factor for Koebner Phenomenon in Psoriasis?

Tildrakizumab is an IL-23-inhibitor that has been approved to treat plaque psoriasis. However, few reports have become available on its efficacy profile in the real-world. Our objective was to study the mid-term efficacy of tildrakizumab […]

Introducción La psoriasis es una enfermedad crónica con una prevalencia del 3% en la población general. Esta alta prevalencia ha impulsado el estudio de sus comorbilidades en las últimas décadas. Sin embargo, no se han […]

Background and objective Real-world evidence of paediatric psoriasis (PsO) is lacking in Spain. The purpose of this study was to identify physician-reported disease burden and current treatment patterns in a real-world paediatric PsO patient cohort […]